Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
copper(II) diethyldithiocarbamate
- Development stage
- Preclinical
- Lead developer
- University of Wolverhampton
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Copper(II) diethyldithiocarbamate (Cu(DDC)2) is a small molecule metal complex and the active anticancer metabolite formed when disulfiram (Antabuse) reacts with copper ions. It is currently being investigated as a potent antineoplastic agent across various solid tumors, including glioblastoma, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. Its mechanism of action is multifaceted, involving the inhibition of the p97 (VCP) segregase pathway, induction of reactive oxygen species (ROS), and inhibition of aldehyde dehydrogenase (ALDH) activity. Due to its poor aqueous solubility and short half-life, research is focused on nanotechnology-based delivery systems, such as albumin-encapsulated nanoparticles (Alb-CuDDC), to improve bioavailability and therapeutic index.
- Other names
- diethyldithiocarbamic acid copper saltbis(diethyldithiocarbamato)copper(II)CAS 13681-87-3CAS13681-87-3CAS-13681-87-3
02
Targets
NPL4 (Nuclear protein localization protein 4 cofactor–valosin-containing protein segregase complex)ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)
Beyond the preview
Go deeper on copper(II) diethyldithiocarbamate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on copper(II) diethyldithiocarbamate.